Effect of early treatment with ivermectin among patients with covid-19.
dc.contributor.author | Reis, Gilmar | |
dc.contributor.author | Silva, Eduardo Augusto dos Santos Moreira | |
dc.contributor.author | Silva, Daniela Carla Medeiros | |
dc.contributor.author | Thabane, Lehana | |
dc.contributor.author | Milagres, Aline Cruz | |
dc.contributor.author | Ferreira, Thiago Santiago | |
dc.contributor.author | Santos, Castilho Vitor Quirino dos | |
dc.contributor.author | Campos, Vitoria H. S. | |
dc.contributor.author | Nogueira, Ana Maria R | |
dc.contributor.author | Almeida, Ana Paula Figueiredo Guimarães de | |
dc.contributor.author | Callegari, Eduardo Diniz | |
dc.contributor.author | Figueiredo Neto, Adhemar Dias de | |
dc.contributor.author | Savassi, Leonardo Cançado Monteiro | |
dc.contributor.author | Simplicio, Maria Izabel Campos | |
dc.contributor.author | Ribeiro, Luciene Barra | |
dc.contributor.author | Oliveira, Rosemary | |
dc.contributor.author | Harari, Ofir | |
dc.contributor.author | Forrest, Jamie I. | |
dc.contributor.author | Ruton, Hinda | |
dc.contributor.author | Sprague, Sheila | |
dc.contributor.author | Mckay, Paula | |
dc.contributor.author | Guo, Christina M. | |
dc.contributor.author | Rowland-Yeo, Kanters | |
dc.contributor.author | Guyatt, Gordon Henry | |
dc.contributor.author | Boulware, David R. | |
dc.contributor.author | Rayner, Craig R. | |
dc.contributor.author | Mills, Edward Joseph | |
dc.date.accessioned | 2023-06-26T20:29:20Z | |
dc.date.available | 2023-06-26T20:29:20Z | |
dc.date.issued | 2022 | pt_BR |
dc.description.abstract | BACKGROUND The efficacy of ivermectin in preventing hospitalization or extended observation in an emergency setting among outpatients with acutely symptomatic coronavirus dis- ease 2019 (Covid-19), the disease caused by severe acute respiratory syndrome coro- navirus 2 (SARS-CoV-2), is unclear. METHODS We conducted a double-blind, randomized, placebo-controlled, adaptive platform trial involving symptomatic SARS-CoV-2–positive adults recruited from 12 public health clinics in Brazil. Patients who had had symptoms of Covid-19 for up to 7 days and had at least one risk factor for disease progression were randomly assigned to receive ivermectin (400 μg per kilogram of body weight) once daily for 3 days or placebo. (The trial also involved other interventions that are not reported here.) The primary composite outcome was hospitalization due to Covid-19 within 28 days after randomization or an emergency department visit due to clinical worsening of Covid-19 (defined as the participant remaining under observation for >6 hours) within 28 days after randomization. RESULTS A total of 3515 patients were randomly assigned to receive ivermectin (679 patients), placebo (679), or another intervention (2157). Overall, 100 patients (14.7%) in the ivermectin group had a primary-outcome event, as compared with 111 (16.3%) in the placebo group (relative risk, 0.90; 95% Bayesian credible interval, 0.70 to 1.16). Of the 211 primary-outcome events, 171 (81.0%) were hospital admissions. Find- ings were similar to the primary analysis in a modified intention-to-treat analysis that included only patients who received at least one dose of ivermectin or placebo (relative risk, 0.89; 95% Bayesian credible interval, 0.69 to 1.15) and in a per-protocol analysis that included only patients who reported 100% adherence to the assigned regimen (relative risk, 0.94; 95% Bayesian credible interval, 0.67 to 1.35). There were no significant effects of ivermectin use on secondary outcomes or adverse events. CONCLUSIONS Treatment with ivermectin did not result in a lower incidence of medical admission to a hospital due to progression of Covid-19 or of prolonged emergency department observation among outpatients with an early diagnosis of Covid-19. (Funded by FastGrants and the Rainwater Charitable Foundation; TOGETHER ClinicalTrials.gov number, NCT04727424.) | pt_BR |
dc.identifier.citation | REIS, G. et al. Effect of early treatment with ivermectin among patients with covid-19. The New England Journal of Medicine, v. 386, n. 18, 2022. Disponível em: <https://www.nejm.org/doi/full/10.1056/nejmoa2115869>. Acesso em: 11 out. 2022. | pt_BR |
dc.identifier.doi | https://doi.org/10.1056/NEJMoa2115869 | pt_BR |
dc.identifier.issn | 1533-4406. | |
dc.identifier.uri | http://www.repositorio.ufop.br/jspui/handle/123456789/16802 | |
dc.identifier.uri2 | https://www.nejm.org/doi/full/10.1056/nejmoa2115869 | pt_BR |
dc.language.iso | en_US | pt_BR |
dc.rights | restrito | pt_BR |
dc.title | Effect of early treatment with ivermectin among patients with covid-19. | pt_BR |
dc.type | Artigo publicado em periodico | pt_BR |
Arquivos
Pacote Original
1 - 1 de 1
Nenhuma Miniatura disponível
- Nome:
- ARTIGO_EffectEarlyTreatment.pdf
- Tamanho:
- 522.37 KB
- Formato:
- Adobe Portable Document Format
- Descrição:
Licença do Pacote
1 - 1 de 1
Nenhuma Miniatura disponível
- Nome:
- license.txt
- Tamanho:
- 1.71 KB
- Formato:
- Item-specific license agreed upon to submission
- Descrição: